Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery
A nanocarrier including a silica body having a surface and defining a plurality of pores that are suitable to receive molecules therein is described. The nanocarrier also includes a lipid bilayer coating the surface, and a cargo-trapping agent within the phospholipid bilayer. The phospholipid bilayer stably seals the plurality of pores. The cargo-trapping reagent can be selected to interact with a desired cargo, such as a drug.
1. A nanoparticle drug carrier comprising:
a silica nanoparticle having a surface and defining a plurality of pores that are suitable to receive molecules therein;
a lipid bilayer coating the surface and encapsulating said nanoparticle;
a cargo-trapping agent disposed within the plurality of pores, wherein the cargo-trapping agent before reaction with a drug is a protonating agent comprising an ammonium salt, trimethylammonium salt, triethylammonium salt, or an ionophore combined with a metal salt; and
a drug consisting of irinotecan wherein said drug is protonated and trapped in the plurality of pores in association with the cargo-trapping agent.
2. The nanoparticle drug carrier of claim 1 , wherein the silica nanoparticle is a mesoporous silica nanoparticle, and the nanoparticle drug carrier has a submicron structure with a maximum dimension of less than one micron.
3. The nanoparticle drug carrier of claim 1 , wherein the lipid bilayer stably seals the plurality of pores.
4. The nanoparticle drug carrier of claim 1 , wherein the drug is protonated and trapped in the plurality of pores as a gel-like precipitate in association with sucrose octasulfate in its anionic form (SOS 8− ).
5. The nanoparticle drug carrier of claim 1 , wherein the lipid bilayer is a phospholipid bilayer.
6. The nanoparticle drug carrier of claim 1 , wherein the lipid bilayer comprises phospholipids, cholesterol, and polyethylene glycol functionalized lipids.
7. The nanoparticle drug carrier of claim 6 , wherein the lipid bilayer comprises 50-90 mol % phospholipids, 10-50 mol % cholesterol, and 1-10 mol % polyethylene glycol functionalized lipids.
8. The nanoparticle drug carrier of claim 1 , wherein the lipid bilayer comprises DSPC/Chol/DSPE-PEG in a molar ratio of about 3:2:0.15 where DSPC is distearoyl phosphatidylcholine, Chol is cholesterol, and DSPE-PEG is distearoyl phosphatidlyehtanolamine bound to polyethylene glycol.
9. The nanoparticle drug carrier of claim 1 , wherein the lipid bilayer forms a substantially continuous bilayer encompassing the nanoparticle surface.
10. The nanoparticle drug carrier of claim 1 , wherein the nanoparticle drug carrier has a drug loading capacity of at least about 40%.
11. The nanoparticle drug carrier of claim 1 , wherein the ammonium salt is selected from the group consisting of ammonium sulfate, ammonium sucrose octasulfate, ammonium α-cyclodextrin sulfate, ammonium β-cyclodextrin sulfate, ammonium γ-cyclodextrin sulfate, ammonium phosphate, ammonium α-cyclodextrin phosphate, ammonium β-cyclodextrin phosphate, ammonium γ-cyclodextrin phosphate, ammonium citrate, and ammonium acetate.
12. The nanoparticle drug carrier of claim 1 , wherein the trimethylammonium salt is selected from the group consisting of trimethylammonium sulfate, trimethylammonium sucrose octasulfate, trimethylammonium α-cyclodextrin sulfate, trimethylammonium β-cyclodextrin sulfate, trimethylammonium γ-cyclodextrin sulfate, trimethylammonium phosphate, trimethylammonium α-cyclodextrin phosphate, trimethylammonium β-cyclodextrin phosphate, trimethylammonium γ-cyclodextrin phosphate, trimethylammonium citrate, and trimethylammonium acetate.
13. The nanoparticle drug carrier of claim 1 , wherein the triethylammonium salt is selected from the group consisting of triethylammonium sulfate, triethylammonium ammonium sucrose octasulfate, triethylammonium α-cyclodextrin sulfate, triethylammonium β-cyclodextrin sulfate, triethylammonium γ-cyclodextrin sulfate, triethylammonium phosphate, triethylammonium α-cyclodextrin phosphate, triethylammonium β-cyclodextrin phosphate, triethylammonium γ-cyclodextrin phosphate, triethylammonium citrate, and trietylammonium acetate.
14. A pharmaceutical formulation comprising a plurality of nanoparticle drug carriers, each nanoparticle drug carrier comprising:
a silica nanoparticle comprising a plurality of pores that are suitable to receive molecules therein;
a lipid bilayer stably sealing the plurality of pores;
a trapping agent disposed within the plurality of pores, wherein the trapping agent before reaction with a drug is an ammonium salt, a trimethylammonium salt, a triethylammonium salt, or an ionophore combined with a metal salt; and
a drug consisting of irinotecan wherein said drug is trapped in the plurality of pores in association with the cargo-trapping agent.
15. The pharmaceutical formulation of claim 14 , wherein the plurality of nanoparticle drug carriers have a submicron structure with a maximum dimension of less than one micron.
16. The pharmaceutical formulation of claim 14 , wherein the plurality of nanoparticle drug carriers has less than about 20% leakage of the drug over 24 hours in a biological buffer with pH of 7.4 at 37° C.
17. The pharmaceutical formulation of claim 14 , wherein the plurality of nanoparticle drug carriers has a drug loading capacity of at least about 40% w/w.
18. The pharmaceutical formulation of claim 14 , wherein the population of the drug carriers in suspension shows a substantially unimodal size distribution with a polydispersity index (PDI) less than about 0.2.